GT Biopharma, Inc. short interest in 2026
In 2026, GT Biopharma, Inc.'s disclosed short interest ran from 22.80% of shares outstanding on 15 Jan 2026 to 8.52% on 31 Aug 2026, a change of -14.28 percentage points. The year's high was 25.30% on 30 Jan 2026 and its low 1.92% on 30 Apr 2026, averaging 10.66% across 10 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 9.99 days on 31 Aug 2026. Full history: GT Biopharma, Inc..
Cite this page
By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2026 in figures
- Start of year
- 22.80% (15 Jan 2026)
- End of year
- 8.52% (31 Aug 2026)
- Change
- -14.28 pp
- High
- 25.30% (30 Jan 2026)
- Low
- 1.92% (30 Apr 2026)
- Average
- 10.66%
- Highest days to cover
- 9.99 (31 Aug 2026)
- SEC filings marked
- 3
Every report in 2026
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2026 | 22.80% | 1.18 | |
| 30 Jan 2026 | 25.30% | 3.37 | |
| 13 Feb 2026 | 24.72% | 1.40 | |
| 27 Feb 2026 | 6.62% | 2.26 | |
| 13 Mar 2026 | 3.23% | 1.40 | 10-K filed |
| 31 Mar 2026 | 2.37% | 1.14 | |
| 15 Apr 2026 | 2.13% | 1.27 | |
| 30 Apr 2026 | 1.92% | 1.00 | |
| 14 Aug 2026 | 9.01% | 9.26 | 10-Q filed, 10-Q filed |
| 31 Aug 2026 | 8.52% | 9.99 |
See also: GT Biopharma, Inc.'s full history · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.